Cancer immunotherapy‐targeted glypican‐3 or neoantigens

Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican‐3 an HLA‐24, HLA‐A2 restriction peptide with extreme cancer s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Shimizu, Yasuhiro, Suzuki, Toshihiro, Yoshikawa, Toshiaki, Tsuchiya, Nobuhiro, Sawada, Yu, Endo, Itaru, Nakatsura, Tetsuya
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Thematic Section: Immunology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834776/
https://ncbi.nlm.nih.gov/pubmed/29285841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13485
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki